INZY vs. FHTX, ZIOP, EGRX, STML, MIRM, PRTA, ARCT, DAWN, CVAC, and ABCL
Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Foghorn Therapeutics (FHTX), ZIOPHARM Oncology (ZIOP), Eagle Pharmaceuticals (EGRX), Stemline Therapeutics (STML), Mirum Pharmaceuticals (MIRM), Prothena (PRTA), Arcturus Therapeutics (ARCT), Day One Biopharmaceuticals (DAWN), CureVac (CVAC), and AbCellera Biologics (ABCL). These companies are all part of the "medical" sector.
Foghorn Therapeutics (NASDAQ:FHTX) and Inozyme Pharma (NASDAQ:INZY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Inozyme Pharma has a net margin of 0.00% compared to Inozyme Pharma's net margin of -274.23%. Inozyme Pharma's return on equity of 0.00% beat Foghorn Therapeutics' return on equity.
Inozyme Pharma received 4 more outperform votes than Foghorn Therapeutics when rated by MarketBeat users. Likewise, 81.82% of users gave Inozyme Pharma an outperform vote while only 59.26% of users gave Foghorn Therapeutics an outperform vote.
In the previous week, Inozyme Pharma had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 1 mentions for Inozyme Pharma and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.87 beat Inozyme Pharma's score of 0.00 indicating that Inozyme Pharma is being referred to more favorably in the news media.
61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 88.3% of Inozyme Pharma shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by insiders. Comparatively, 11.2% of Inozyme Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Inozyme Pharma has lower revenue, but higher earnings than Foghorn Therapeutics. Inozyme Pharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Foghorn Therapeutics has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500. Comparatively, Inozyme Pharma has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
Foghorn Therapeutics presently has a consensus target price of $14.50, suggesting a potential upside of 141.26%. Inozyme Pharma has a consensus target price of $16.40, suggesting a potential upside of 254.21%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inozyme Pharma is more favorable than Foghorn Therapeutics.
Summary
Inozyme Pharma beats Foghorn Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Inozyme Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inozyme Pharma Competitors List
Related Companies and Tools
